Clinical Trial

Treatment Strategy for Patients With RA-ILD

Name: Treatment Strategy for Patients With RA-ILD — clinical trial record (NCT07643038)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.

Trial Details

NCT Number	NCT07643038
Lead Sponsor	Chinese SLE Treatment And Research Group
Conditions	Rheumatoid Arthritis Associated Interstitial Lung Disease
Enrollment	204 participants
Start Date	2026-07-01
Primary Completion	2029-07-31 (estimated)
Study Completion	2029-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-11